Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree

View original at finance.yahoo.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree If any investor has stood the test of time, it’s Warren Buffett, and with good reason…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The portfolio will remain concentrated in a small group of companies

    60% confidence

  • Warren Buffett vows to come to the office every day and continue to have a voice in day-to-day operations

    60% confidence

  • Warren Buffett will remain board chair and come to the office every day, continuing to have a voice in day-to-day operations

    60% confidence

  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it. The portfolio will remain concentrated in a small group of companies.

    60% confidence

  • The course forward would remain the same, and he would directly oversee the equity portfolio, with Ted Weschler continuing to manage about 6% of it

    60% confidence

  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence

  • Greg Abel will use all of his $25 million per year salary to buy shares in Berkshire Hathaway

    60% confidence

  • Warren Buffett's favorite holding period for an S&P 500 stock is forever

    60% confidence

  • His favorite holding for an S&P 500 stock is forever

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
5 Dividend Stocks Are 60% of Berkshire Hathaway After Buffett’s Q4 Selling Spree — Source | Via News | ViaNews EU